What's in Zahra Vahdat Shariatpanahi's pipeline?

Zahra Vahdat Shariatpanahi has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Zahra Vahdat Shariatpanahi's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zahra-vahdat-shariatpanahi.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zahra Vahdat Shariatpanahi — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zahra Vahdat Shariatpanahi pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Iramox	Iramox	marketed	Other
Tavanex	Tavanex	marketed	Other
Lanzol	Lanzol	marketed	Other
Klacid	Klacid	marketed	Other
Tinafas	Tinafas	marketed	Other

Therapeutic area mix

Other · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Zahra Vahdat Shariatpanahi:

Cite this brief

Drug Landscape (2026). Zahra Vahdat Shariatpanahi — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zahra-vahdat-shariatpanahi. Accessed 2026-05-17.